Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn

Company News Summary

Telix Pharmaceuticals Reports Net Loss of $32.51m for Half-Year to 30 June 2021

19 Oct 2021  |  16:29:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: App 4D and Report for Half-Year Ended 30 June 2021

Telix Pharmaceuticals reported net loss of $32.51m for the half-year ended 30 June 2021. Revenue from ordinary activities were $2.9m. Basic and Diluted EPS were (11.56) cents compared to (7.22) cents last year. The net operating cash outflow was $28.65m compared to an outflow of $18.47m in the pcp. No dividend was declared.

Telix Pharmaceuticals Half Year Results to 30 June 2021

6 Months to 30 June 2021 ($A'000) 6 Months to 30 June 2020 ($A'000)
Revenue 2,910 1,607
Pre-Tax Profit (Loss) (32,448) (19,246)
Net Profit (Loss) (32,514) (18,301)
Operating Cash Flow (28,648) (18,472)
Interim Dividends (cents) nil nil
Basic and Diluted EPS (cents) (11.56) (7.22)
NTA (cents) (3) 4
Please click here for full details

See more ASX300 News Announcements